Newton, MA– GlycoEra AG, a biotechnology company developing extracellular protein degraders for autoimmune diseases, has secured $130 million in an oversubscribed Series B financing round. The funding will support the advancement of its lead therapeutic candidate and expansion of its precision immunology pipeline.
The round was led by Novo Holdings and included new investors such as Catalio Capital Management, LifeArc Ventures, and the Qatar Investment Authority (QIA). Existing backers including Sofinnova Partners, 5AM Ventures, Roche Ventures, and Bristol Myers Squibb also participated. Additional new investors joining the syndicate include Agent Capital, MP Healthcare Venture Management, and Sixty Degree Capital.
GlycoEra plans to use the proceeds to bring its lead program, GE8820, into first-in-human clinical trials later this year. GE8820 is designed to selectively degrade pathogenic IgG4 autoantibodies, which are implicated in several autoimmune diseases including MuSK myasthenia gravis, pemphigus, primary membranous nephropathy, and autoimmune encephalitis. Preclinical data suggest the therapy can achieve deep and rapid IgG4 depletion with high specificity and without broad immunosuppression.
“This financing is a strong validation of our platform and pipeline,” said GlycoEra CEO Dr. Ganesh Kaundinya. “With the support of world-class investors, we are accelerating development of GE8820 and advancing our broader portfolio of precision immunology therapeutics.”
The company’s proprietary protein degradation platform uses bispecific recombinant molecules to target and eliminate extracellular proteins. Unlike traditional synthetic approaches, GlycoEra’s one-step recombinant process enables scalable, modular development of highly selective protein degraders.
Novo Holdings partner Max Klement praised the potential of GE8820 as a “paradigm-shifting” therapy, while Sofinnova Partners Managing Partner Graziano Seghezzi, a founding investor in the company, highlighted the unique promise of GlycoEra’s platform.
Alongside the financing, GlycoEra also announced the appointment of Max Klement, Matthew Hobson of Catalio Capital Management, and Sohaib Mir of LifeArc Ventures to its board of directors.
